Con­gress fires an­oth­er sal­vo at Al­ler­gan’s Mo­hawk deal; AI out­fit rais­es $60M for dis­cov­ery ef­fort

→ Al­ler­gan’s move to try and steer around an IPR re­view of its patents for its $1.5 bil­lion drug Resta­sis by hand­ing them over to an In­di­an tribe for safe­keep­ing was tai­lor made for pub­lic con­tro­ver­sy. And law­mak­ers have proved oblig­ing. Now a bi­par­ti­san group of House mem­bers are set­ting up a probe of the deal, which re­lies on the sov­er­eign im­mu­ni­ty of the Saint Reg­is Mo­hawk tribe to block the IPR. Al­ler­gan CEO Brent Saun­ders wants this to be a fight about the IPR process — what he’s wound up with is a PR bat­tle with al­most no chance of win­ning.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.